# US 10,766,959 B2 · Anti-C10ORF54 antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,766,959 B2
- Document ID: US10766959B2
- Status: Granted
- Kind: B2
- Application number: 15/534,982
- Filed: 2015-12-11
- Published: 2019-06-13
- Granted: 2020-09-08
- Earliest claimed: 2014-12-11
- Assignees: Pierre Fabre Medicament
- Applicants: Pierre Fabre Medicament
- Inventors: John Lippincott; Edward Thein Htun Van Der Horst; Sung Young Kim; Leonard G Presta; Jan-Willem Theunissen
- Web page: https://patentgrep.com/patent/US10766959B2

## CPC

- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/68035: {the drug being a pyrrolobenzodiazepine}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6873: {the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody}
- A61P 35/00: Antineoplastic agents
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/74: Inducing cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.

## Claims

### Claim 1

An isolated antibody or antigen-binding fragment thereof that binds to a C10orf54 protein, comprising:
a heavy chain comprising the following three CDRs, respectively CDR-H1 having the sequence SEQ ID NO: 1296, CDR-H2 having a sequence selected from SEQ ID NO: 1358, SEQ ID NO. 1556, SEQ ID NO. 1557, SEQ ID NO. 1558, and SEQ ID NO. 1559, and CDR-H3 having the sequence SEQ ID No. 1393; and
a light chain comprising the following three CDRs, respectively CDR-L1 having the sequence SEQ ID No. 1435, CDR-L2 having a sequence selected from SEQ ID NO: 1476, SEQ ID NO. 1630, SEQ ID NO. 1631, SEQ ID NO. 1632, and SEQ ID NO. 1633, and CDR-L3 having the sequence SEQ ID No. 1499.

### Claim 2 (depends on 1)

The antibody of claim 1, or the antigen-binding fragment thereof, wherein said antibody is humanized.

### Claim 3 (depends on 2)

The antibody according to claim 2, or the antigen-binding fragment thereof, said antibody comprising a heavy chain variable domain of sequence selected between amino acid sequences SEQ ID NO. 1529, SEQ ID NO. 1530, and SEQ ID NO. 1531, and a light chain variable domain of sequence selected between amino acid sequences SEQ ID NO. 1532, SEQ ID NO. 1533, and SEQ ID NO. 1534.

### Claim 4 (depends on 1)

The antibody of claim 1, wherein the antibody is a Fab fragment, F(ab′)2 fragment, single chain Fv (sFv), diabody, triabody, or minibody.

### Claim 5 (depends on 1)

The antibody of claim 1, or antigen-binding fragment thereof, wherein said antibody is a monoclonal antibody.

### Claim 6 (depends on 1)

An antibody-drug conjugate comprising the antibody of claim 1 conjugated to a cytotoxic agent.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable diluent, carrier or excipient.

### Claim 8 (depends on 6)

A pharmaceutical composition comprising the antibody-drug conjugate of claim 6 and a pharmaceutically acceptable diluent, carrier or excipient.

### Claim 9 (depends on 1)

A kit comprising the antibody of claim 1.

### Claim 10 (depends on 9)

The kit of claim 9, wherein said antibody is conjugated to a detectable substrate.

### Claim 11 (depends on 1)

A polynucleotide comprising a nucleotide sequence encoding the antibody of claim 1.

### Claim 12 (depends on 11)

An expression vector comprising the polynucleotide of claim 11.

### Claim 13 (depends on 12)

An isolated host cell comprising the expression vector of claim 12.

### Claim 14 (depends on 1)

A method of producing the antibody or antigen-binding fragment thereof, of claim 1, said method comprising a step of culturing a host cell comprising an expression vector comprising a polynucleotide encoding the antibody of claim 1 under conditions that promote the production of the antibody.

### Claim 15 (depends on 1)

A method of detecting, in vitro, a C10orf54 protein in a sample comprising contacting the sample with the antibody of claim 1.